|
|
Article: New Phase III data for Neurocrine's indiplon.(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- March 1, 2004
CopyrightCOPYRIGHT 2004 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences has released promising results from a Phase III trial evaluating an immediate-release formulation of its indiplon in elderly patients with chronic insomnia.
The randomized, placebo-controlled, double-blind, parallel group, outpatient study assessed the safety and efficacy of 5mg and 10mg immediate-release indiplon in 360 patients. Subjects were evaluated over a two-week treatment period and were eligible to continue in a six-month open-label extension of this trial, noted the company.
Results showed that the primary endpoint of the study, latency to sleep onset (ie, the time taken to fall asleep) as measured by patient ...